Cancer Trials: Patient-Reported Outcomes Should Measure Five Core Concepts, US FDA Says

 
• By Sue Sutter

Heterogeneity in PRO assessment strategies has lessened the regulatory utility of such data from cancer trials, the agency says; new draft guidance recommends systematic assessment of a core set of PROs in registrational studies using fit-for-purpose tools and includes examples of acceptable instruments.  

Apple core
US FDA has suggested a set of core concepts on which it would like to see PRO data from cancer registrational trials. • Source: Alamy

More from Clinical Trials

More from R&D